v3.26.1
Shareholders’ equity
 3 Months Ended
Mar. 31, 2026
Notes and other explanatory information [abstract]  
Shareholders’ equity
10.Shareholders’ equity

 

Share capital

 

The Company has authorized an unlimited number of common shares (being voting and participating shares) with no par value, as well as an unlimited number of preferred, first and second ranking shares, issuable in series, with rights and privileges specific to each class, with no par value.

 

   Common shares   Amount 
   #   $ 
Balance – December 31, 2025   3,183,330    22,624 
Granted   829    1 
Balance – March 31, 2026   3,184,159    22,625 

 

   Common shares   Amount 
   #   $ 
Balance – December 31, 2024   3,140,621    22,486 
Granted   5,595    17 
Balance – March 31, 2025   3,146,216    22,503 

 

 

COSCIENS Biopharma Inc.

Notes to the Condensed Interim Consolidated Financial Statements

As of March 31, 2026, and for the three months ended March 31, 2026, and 2025

(In thousands of US dollars, except share and per share data and as otherwise noted)

(Unaudited)

 

Share-based compensation

 

The compensation expense for the three months ended March 31, 2026, was $1 (2025 – $6) recognized over the vesting period. Option activity for the three months ended March 31, 2026, and 2025, was as follows:

 

   Stock options   Weighted average exercise price 
   #   $ 
Balance – January 1, 2026   48,181    31.27 
Cancelled / Forfeited   (4,366)   (15.54)
Balance – March 31, 2026   43,815    32.84 

 

   Stock options   Weighted average exercise price 
   #   $ 
Balance – January 1, 2025   76,024    25.77 
Cancelled / Forfeited   (24,395)   15.92 
Balance – March 31, 2025   51,629    30.43